Experienced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Matthew L. Fero

Hematology Oncology | Oncology | Hematology
Unm Medical Group Inc
2211 Lomas Blvd Ne, 
Albuquerque, NM 
Offers Telehealth
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Unm Medical Group Inc
2211 Lomas Blvd Ne, 
Albuquerque, NM 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Fero is a Hematologist Oncology specialist and an Oncologist in Albuquerque, New Mexico. Dr. Fero is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Multiple Myeloma, Classical Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia (CLL).

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in WA
Hospital Affiliations
Unm Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL

Locations

UNM MEDICAL GROUP INC
2211 Lomas Blvd Ne, Albuquerque, NM 87106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

5 Total Publications

The miR-106a~363Xpcl1 miRNA cluster induces murine T cell lymphoma despite transcriptional activation of the p27Kip1 cell cycle inhibitor.
The miR-106a~363Xpcl1 miRNA cluster induces murine T cell lymphoma despite transcriptional activation of the p27Kip1 cell cycle inhibitor.
Journal: Oncotarget
Published: November 15, 2016
Similar Doctors
Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Tara B. Gregory
Hematology Oncology | Hematology | Oncology
Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Tara B. Gregory
Hematology Oncology | Hematology | Oncology

Healthone Clinic Services - Oncology Hematology LLC

490 W Zia Rd, Suite A, 
Santa Fe, NM 
 (53.7 miles away)
505-913-8951
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tara Gregory is a Hematologist Oncology specialist and a Hematologist in Santa Fe, New Mexico. Dr. Gregory is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Dulcinea D. Quintana
Hematology | Oncology
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Dulcinea D. Quintana
Hematology | Oncology

Unm Medical Group Inc

2211 Lomas Blvd Ne, 
Albuquerque, NM 
 (0.1 miles away)
505-272-2111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dulcinea Quintana is a Hematologist and an Oncologist in Albuquerque, New Mexico. Dr. Quintana is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Primary Amyloidosis, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Multiple Myeloma.

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Luke J. Mountjoy
Hematology Oncology | Hematology
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Luke J. Mountjoy
Hematology Oncology | Hematology

Healthone Clinic Services - Oncology Hematology LLC

490 W Zia Rd, Suite A, 
Santa Fe, NM 
 (53.7 miles away)
505-913-8951
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luke Mountjoy is a Hematologist Oncology specialist and a Hematologist in Santa Fe, New Mexico. Dr. Mountjoy is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fero's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile